Sylvia Shoffner, MD
Internal Medicine · Cary, NCNPI 1912049669
Payments from drug & device makers
Across 774 payments — averaging $9131.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.4M
- Bavarian Nordic A/s$1.5M
- Johnson & Johnson$851K
- GSK$639K
- Boehringer Ingelheim$554K
- Hoffmann-la Roche Limited$313K
- plus $750K from 23 others
What the payments were for
- Travel & lodging$94350%
- Food & beverage$89348%
- Education$151%
- Gifts$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 214 | $2,441,066 |
| Bavarian Nordic A/s | 80 | $1,519,300 |
| Johnson & Johnson | 20 | $851,246 |
| GSK | 128 | $638,811 |
| Boehringer Ingelheim | 30 | $554,029 |
| Hoffmann-la Roche Limited | 11 | $313,167 |
| Idorsia Pharmaceuticals US Inc | 15 | $195,915 |
| Genentech, Inc. | 35 | $182,858 |
| Regeneron | 34 | $142,691 |
| H. Lundbeck A S | 52 | $109,293 |
| F. Hoffmann-la Roche AG | 10 | $47,162 |
| Boehringer Ingelheim International GmbH | 111 | $22,600 |
| AstraZeneca | 4 | $19,873 |
| Tolmar, Inc. | 7 | $12,903 |
| Merck | 1 | $10,500 |
| Astrazeneca UK Limited | 2 | $5,500 |
| Eli Lilly | 1 | $608 |
| Abbott | 5 | $113 |
| Astellas Pharma US Inc | 3 | $55 |
| AbbVie | 2 | $48 |
| Novo Nordisk | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amgen | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$7,067,900 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $127,281 |
| JanuviaSitagliptin Phosphate | 59 | $55,479 |
| EliquisApixaban | 39 | $41,719 |
| JardianceEmpagliflozin | 33 | $38,308 |
| MyrbetriqMirabegron | 31 | $27,728 |
| FarxigaDapagliflozin Propanediol | 23 | $22,121 |
| XareltoRivaroxaban | 22 | $19,597 |
| WegovySemaglutide | 11 | $15,071 |
| SynthroidLevothyroxine Sodium | 117 | $8,663 |
| ConcertaMethylphenidate Hcl | 11 | $8,583 |
| BystolicNebivolol Hcl | 15 | $8,186 |
| LinzessLinaclotide | 11 | $6,636 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,959 |
| Estradiol | 38 | $4,338 |
| Levothyroxine Sodium | 366 | $4,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $24 | $142,352120 claims |
| MerckJanuvia | $10,500 | $55,47959 claims |
| PfizerEliquis | $2,441,066 | $41,71939 claims |
| Boehringer IngelheimJardiance | $554,029 | $38,30833 claims |
| Johnson & JohnsonXarelto, Concerta | $851,246 | $28,18033 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $27,72831 claims |
| AstraZenecaFarxiga | $19,873 | $22,12123 claims |
| AbbVieSynthroid, Linzess | $48 | $15,300128 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $13 | $8,18615 claims |
| GSKBreo Ellipta | $638,811 | $5,95911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Cary
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
- Nitin DesaiFayetteville$6.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.